US3865831A - 1,1{40 ,4,4{40 -tetrahydro-4,4{40 -dioxo(6,6{40 biquinoline)-2,2{40 -dicarboxylates - Google Patents
1,1{40 ,4,4{40 -tetrahydro-4,4{40 -dioxo(6,6{40 biquinoline)-2,2{40 -dicarboxylates Download PDFInfo
- Publication number
- US3865831A US3865831A US261524A US26152472A US3865831A US 3865831 A US3865831 A US 3865831A US 261524 A US261524 A US 261524A US 26152472 A US26152472 A US 26152472A US 3865831 A US3865831 A US 3865831A
- Authority
- US
- United States
- Prior art keywords
- hydrogen
- compound
- biquinoline
- dioxo
- tetrahydro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 150000001875 compounds Chemical class 0.000 claims abstract description 49
- -1 amine salt Chemical class 0.000 claims description 44
- 239000001257 hydrogen Substances 0.000 claims description 32
- 229910052739 hydrogen Inorganic materials 0.000 claims description 32
- 125000004432 carbon atom Chemical group C* 0.000 claims description 23
- 229910052783 alkali metal Inorganic materials 0.000 claims description 20
- 150000001340 alkali metals Chemical group 0.000 claims description 20
- 150000002431 hydrogen Chemical group 0.000 claims description 17
- 239000002253 acid Substances 0.000 claims description 13
- 125000000217 alkyl group Chemical group 0.000 claims description 13
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 11
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 8
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 7
- 125000003545 alkoxy group Chemical group 0.000 claims description 5
- 229910052736 halogen Inorganic materials 0.000 claims description 5
- 150000002367 halogens Chemical class 0.000 claims description 5
- 125000001153 fluoro group Chemical group F* 0.000 claims description 4
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 claims description 3
- 241001465754 Metazoa Species 0.000 abstract description 6
- RZZPDXZPRHQOCG-OJAKKHQRSA-O CDP-choline(1+) Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OCC[N+](C)(C)C)O[C@H]1N1C(=O)N=C(N)C=C1 RZZPDXZPRHQOCG-OJAKKHQRSA-O 0.000 abstract description 5
- 238000011321 prophylaxis Methods 0.000 abstract description 5
- 206010020751 Hypersensitivity Diseases 0.000 abstract description 4
- 239000003937 drug carrier Substances 0.000 abstract description 4
- 208000026935 allergic disease Diseases 0.000 abstract description 3
- 230000007815 allergy Effects 0.000 abstract description 3
- 208000003455 anaphylaxis Diseases 0.000 abstract description 3
- 230000001404 mediated effect Effects 0.000 abstract description 3
- 239000000203 mixture Substances 0.000 description 19
- 230000008859 change Effects 0.000 description 17
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 11
- 239000000843 powder Substances 0.000 description 11
- 238000000034 method Methods 0.000 description 9
- 239000000443 aerosol Substances 0.000 description 8
- 239000004615 ingredient Substances 0.000 description 8
- 239000003380 propellant Substances 0.000 description 8
- 239000003826 tablet Substances 0.000 description 8
- CCKFFRXAFQLLDF-UHFFFAOYSA-N 6-quinolin-6-ylquinoline Chemical compound N1=CC=CC2=CC(C=3C=CC4=NC=CC=C4C=3)=CC=C21 CCKFFRXAFQLLDF-UHFFFAOYSA-N 0.000 description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- HFACYLZERDEVSX-UHFFFAOYSA-N benzidine Chemical class C1=CC(N)=CC=C1C1=CC=C(N)C=C1 HFACYLZERDEVSX-UHFFFAOYSA-N 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 7
- 239000002552 dosage form Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 239000007858 starting material Substances 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- 208000006673 asthma Diseases 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical compound C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 239000003981 vehicle Substances 0.000 description 6
- 150000001412 amines Chemical group 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical class OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 239000000376 reactant Substances 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- MHCVCKDNQYMGEX-UHFFFAOYSA-N 1,1'-biphenyl;phenoxybenzene Chemical compound C1=CC=CC=C1C1=CC=CC=C1.C=1C=CC=CC=1OC1=CC=CC=C1 MHCVCKDNQYMGEX-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 239000011149 active material Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- YTIVTFGABIZHHX-UHFFFAOYSA-N butynedioic acid Chemical compound OC(=O)C#CC(O)=O YTIVTFGABIZHHX-UHFFFAOYSA-N 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000007903 gelatin capsule Substances 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 235000010981 methylcellulose Nutrition 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 3
- 239000008024 pharmaceutical diluent Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000006798 ring closing metathesis reaction Methods 0.000 description 3
- 238000007363 ring formation reaction Methods 0.000 description 3
- BUBOVHRAKJTFKI-UHFFFAOYSA-M sodium;4-hydroxy-2,4-dioxobutanoate Chemical compound [Na+].OC(=O)C(=O)CC([O-])=O BUBOVHRAKJTFKI-UHFFFAOYSA-M 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- GOJHDSPKKWASRH-UHFFFAOYSA-N 5-amino-2-(4-aminophenyl)benzonitrile Chemical compound C1=CC(N)=CC=C1C1=CC=C(N)C=C1C#N GOJHDSPKKWASRH-UHFFFAOYSA-N 0.000 description 2
- 241000220479 Acacia Species 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- VOPWNXZWBYDODV-UHFFFAOYSA-N Chlorodifluoromethane Chemical compound FC(F)Cl VOPWNXZWBYDODV-UHFFFAOYSA-N 0.000 description 2
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 2
- 208000004262 Food Hypersensitivity Diseases 0.000 description 2
- 206010016946 Food allergy Diseases 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 206010039085 Rhinitis allergic Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 150000001335 aliphatic alkanes Chemical class 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 201000010105 allergic rhinitis Diseases 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 239000008135 aqueous vehicle Substances 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- AFYPFACVUDMOHA-UHFFFAOYSA-N chlorotrifluoromethane Chemical compound FC(F)(F)Cl AFYPFACVUDMOHA-UHFFFAOYSA-N 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 2
- 229940038472 dicalcium phosphate Drugs 0.000 description 2
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 2
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 2
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 2
- 229960004132 diethyl ether Drugs 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000020932 food allergy Nutrition 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 125000000468 ketone group Chemical group 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 239000006199 nebulizer Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- KHPXUQMNIQBQEV-UHFFFAOYSA-N oxaloacetic acid Chemical compound OC(=O)CC(=O)C(O)=O KHPXUQMNIQBQEV-UHFFFAOYSA-N 0.000 description 2
- 150000004727 oxaloacetic acid derivatives Chemical class 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 238000001953 recrystallisation Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- BOSAWIQFTJIYIS-UHFFFAOYSA-N 1,1,1-trichloro-2,2,2-trifluoroethane Chemical compound FC(F)(F)C(Cl)(Cl)Cl BOSAWIQFTJIYIS-UHFFFAOYSA-N 0.000 description 1
- BAMUEXIPKSRTBS-UHFFFAOYSA-N 1,1-dichloro-1,2,2,2-tetrafluoroethane Chemical compound FC(F)(F)C(F)(Cl)Cl BAMUEXIPKSRTBS-UHFFFAOYSA-N 0.000 description 1
- NPNPZTNLOVBDOC-UHFFFAOYSA-N 1,1-difluoroethane Chemical compound CC(F)F NPNPZTNLOVBDOC-UHFFFAOYSA-N 0.000 description 1
- JPZRPCNEISCANI-UHFFFAOYSA-N 4-(4-aminophenyl)-3-(trifluoromethyl)aniline Chemical compound C1=CC(N)=CC=C1C1=CC=C(N)C=C1C(F)(F)F JPZRPCNEISCANI-UHFFFAOYSA-N 0.000 description 1
- ZNDJZRZZTPORNT-UHFFFAOYSA-N 4-(4-aminophenyl)-5,5-dimethylcyclohexa-1,3-dien-1-amine Chemical compound CC1(C)CC(N)=CC=C1C1=CC=C(N)C=C1 ZNDJZRZZTPORNT-UHFFFAOYSA-N 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010003557 Asthma exercise induced Diseases 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 208000004657 Exercise-Induced Asthma Diseases 0.000 description 1
- 241000243251 Hydra Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229930194542 Keto Natural products 0.000 description 1
- 125000000174 L-prolyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(*)=O 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- SOWBFZRMHSNYGE-UHFFFAOYSA-N Monoamide-Oxalic acid Natural products NC(=O)C(O)=O SOWBFZRMHSNYGE-UHFFFAOYSA-N 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical group [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001348 alkyl chlorides Chemical class 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- UMNKXPULIDJLSU-UHFFFAOYSA-N dichlorofluoromethane Chemical compound FC(Cl)Cl UMNKXPULIDJLSU-UHFFFAOYSA-N 0.000 description 1
- 229940099364 dichlorofluoromethane Drugs 0.000 description 1
- VHILMKFSCRWWIJ-UHFFFAOYSA-N dimethyl acetylenedicarboxylate Chemical compound COC(=O)C#CC(=O)OC VHILMKFSCRWWIJ-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 208000024695 exercise-induced bronchoconstriction Diseases 0.000 description 1
- FPVGTPBMTFTMRT-NSKUCRDLSA-L fast yellow Chemical compound [Na+].[Na+].C1=C(S([O-])(=O)=O)C(N)=CC=C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 FPVGTPBMTFTMRT-NSKUCRDLSA-L 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 125000001188 haloalkyl group Chemical group 0.000 description 1
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- QRXWMOHMRWLFEY-UHFFFAOYSA-N isoniazide Chemical compound NNC(=O)C1=CC=NC=C1 QRXWMOHMRWLFEY-UHFFFAOYSA-N 0.000 description 1
- 239000000644 isotonic solution Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- IZXGZAJMDLJLMF-UHFFFAOYSA-N methylaminomethanol Chemical compound CNCO IZXGZAJMDLJLMF-UHFFFAOYSA-N 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- SNMVRZFUUCLYTO-UHFFFAOYSA-N n-propyl chloride Chemical class CCCCl SNMVRZFUUCLYTO-UHFFFAOYSA-N 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000011591 potassium Chemical group 0.000 description 1
- 229910052700 potassium Chemical group 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- QHMQWEPBXSHHLH-UHFFFAOYSA-N sulfur tetrafluoride Chemical compound FS(F)(F)F QHMQWEPBXSHHLH-UHFFFAOYSA-N 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- XJDNKRIXUMDJCW-UHFFFAOYSA-J titanium tetrachloride Chemical compound Cl[Ti](Cl)(Cl)Cl XJDNKRIXUMDJCW-UHFFFAOYSA-J 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 238000005809 transesterification reaction Methods 0.000 description 1
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
- 229940029284 trichlorofluoromethane Drugs 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 150000004684 trihydrates Chemical class 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
Definitions
- DICARBOXYLATES The preferred compounds are those compounds where R is selected from the group consisting of hydro- 5 gen, alkali metal and an amine salt; Z is hydrogen.
- novel compounds of For- When X and Y are the same monosubstituentQthey are mula Ia are useful in the prophylactic treatment of senselected from the group consisting of hydrogen. alkyl sitized humans and animals for allergy and all anaphyfrom one to three carbon atoms, inclusive, alkoxy from lactic reactions ofa reagin or non-reagin mediated naone to three carbon atoms, inclusive. halogen. cyano, ture.
- the compounds are formulated with pharmaceuand tical carriers for oral, parenteral, or insufflation means 0 of administration. C 0.
- Q is selected from the group consisting of hy- DETAILED DESCRIPTION OF THE INVENTION l5 drogen, alkali metal and an amine salt, with the proviso
- Q is the same as R; and with the same aforemenpounds represented by structure la tioned restriction on the location of the monosubstitu- OR la wherein it is understood that la can exist in its tautoents.
- R substituent is selected from the group consisthydrogen, fluoro, chloro, methyl, ethyl, methoxy, ething of hydrogen, alkyl from one to three carbon atoms, oxy, cyano, and inclusive, phenyl, alkali metal or an amine salt.
- Z is selected from the group consisting of hydrogen, -&
- halogen includes fluoro, where Q is selected from the group consisting of hydrochloro, bromo, and iodo and the term alkyl includes gen; alkyl from one to three carbon atoms, inclusive; methyl, ethyl, propyl, and isopropyl when limited to phenyl; an alkali metal and an amine salt, with the prothree carbon atoms.
- Alkali metal includes sodium viso that where R is hydrogen, alkali metal or an amine and potassium.
- amine salt includes all salt, when Q must be the same as R; with the further pharmaceutically acceptable amine salts of the invenprovision that when tion, including, for example, the amines ammonia, trisa.
- X is at the 5 position, Y is at the 5' or 7' position, (hydroxymethyl)-aminomethane, D-threo-2-aminolb.
- X is at the 7 position, Y is at the 5 or 7' position, p-nitrophenyl-l ,3-propanediol, N,N- c.
- X is at the 8 position
- Y is at the 8 position
- the compounds of this invention can be prepared by methods known to the art.
- the basic synthetic pathway employed is the reaction of an appropriately substituted benzidine (II) with an oxaloacetate sodium salt (III) in the presence of a solvent to form the diadduct (IV).
- the R group is limited to the alkyl group of from one to three carbon atoms, inclusive; and phenyl. Ring closure to the desired compound (la) is accomplished by heating the diadduct at appropriate conditions.
- these 3 Cl 3'c1 compounds are the 5 5, 5 7, and 7 7' disubstituted ZP P 1,1, 4,4-tetrahydro-4,4'-dioxo[6,6'-biquinoline]-2,2'- 3 0iC H 3OiC,,H dicarboxylic acid.
- the compounds of the invention are diethyl 5,5'-dimethyl-l 4,4'-tetrahydro-4,4'- 3 Br 3'Br dioxo[6,6-biquinoline]-2,2'-dicarboxylate, diethyl gg gig 5,7-dimethyl-l,l 4,4'-tetrahydro-4,4-dioxo[6,6- 2 N0 2'NO biquinoline]-2,2'-dicarboxylate, and diethyl 7,7- 2 F dimethyl-l ,l 4,4-tetrahydro-4,4-dioxo[6,6- biquinoline]-2,2'-dicarboxylate.
- X and Y substituted benzidines where X and Y are the same monosubstituent or where either X orY is hydrogen, have been prepared in the art prior to this inexample, trifluoromethyl benzidine is prepared by reacting sulfur tetrafluoride with carboxy-paradinitrobiphenyl followed by reduction to the benzine starting compound.
- the carboxyamide is prepared by reacting the carboxy-para-dinitrobiphenyl with thionyl chloride followed by ammonia treatment to give the carboxyamide-para-dinitrobiphenyl This compound is then readily reduced by either of the methods described above to the corresponding benzidine compound.
- cyanobenzidine is prepared by reacting carboxyamide-para-dinitrobiphenyl with titanium tetrachloride in tetrahydrofuran and base at 0 C. to give the cyano-para-dinitrobiphenyl compound which is readily reduced by either of the methods disclosed above to the cyanobenzidine.
- the second reactant, the oxaloacetate derivative is also readily available.
- R is ethyl and Z is hydrogen, methyl, ethyl or phenyl are known in the art.
- the oxaloacetate reagent When using the oxaloacetate reagent to form the diadduct, there should be a sufficient amount of acid present to protonate the oxaloacetate carbanion and catalyze the removal of the keto grouping as water.
- the acid can also serve as a solvent for the two reagents as well.
- glacial acetic acid, propionic acid, p-toluene sulfonic acid, and butyric acid are acids which can be used.
- a further reagent is needed to place the two reactants into solution, (or a cosolvent desired), benzene, toluene, diethyl ether, dioxane, tetrahydrofuran, or alcohols from one to about four carbon atoms can be employed.
- the length of time for the formation of the diadduct is temperature dependent.
- reaction time is decreased. Acceptable reaction times are achieved at temperatures ranging from about 40 to about (7.. although reaction temperatures can be above C. if desired.
- appropriate solvents are alcohols having from one to about six carbon atoms. preferably one to about three carbon atoms, benzene, diethylether, dioxane, tetrahydrofuran, or any other solvent which places both of the reactants in solution and allows the desired compound to form.
- the reaction proceeds readily at room temperature and can be promoted by an increase in temperature to about 100 C.
- Ring closure of the diadduct, prepared by the methods disclosed above, and formation of the desired compound can be accomplished by heating the diadduct at a relatively high temperature. This heating can be done to the neat diadduct. However, it is preferred to use a solvent which can function as a heat transfer medium. Any high boiling inert solvent such as a mineral oil, hexamethylphosphoric triamide, diphenyl ether, or Dowtherm A, which appears to be primarily a diphenyl ether side product of the Dow Chemical Company preparation of phenol, is suitable.
- the ring cyclization step is preferably carried outlat temperatures of from about 220 C. to about 280 (3., although lower or higher temperatures can be employed ifdesired. Particularly preferred solvents are Dowtherm A, or diphenyl ether, which boil at about 250 C., thus enabling the ring cyclization to occur during reflux.
- An additional advantage of the elevated temperature during the ring cyclization step is that any adduct formed in the preceding step which is not in a position to cyclize since it is trans to the benzene ring is isomerized to the cis configuration during the heating, thereby allowing substantial yields of the desired compound to be produced.
- This trans adduct preparation occurs more frequently when an aprotic solvent and acetylene dicarboxylate are used in the adduct formation step.
- various esters, the acid, or salts can be prepared at the R position of the carboxy group. Different esters can be prepared by a standard transesterification reaction. Ester groups are converted to the acid by treatment with base and acid.
- the acid can then be easily converted to an amine salt or alkali metal by contacting the diacid with two equivalents of the desired amine or alkali metal and heating in-a sufficient amount of water to effect solubilization.
- the crystalline salts can be precipitated by the addition of methanol.
- Example 2 Disodium-l l ',-4,4'-tetrahydro-4,4'-dioxo-[6,6- biquinoline]-2,2-dicarboxylate
- the acid'prepared in Example 1 is converted to its sodium salt by treatment with an approximately halfsaturated, hot solution of NaHCO
- the disodium salt precipitates upon cooling. Recrystallization from water gives the disodium compound as its trihydrate.
- compositions of the present invention are presented for administration to humans and animals in unit dosage forms, such as tablets, capsules, pills, powders, granules, sterile parenteral solutions or suspensions, and oral solutions or suspensions, and oil-in-water and water-inoil emulsions containing suitable quantities of the compound of Formula la.
- the preferred method of administration is by inhalation into the lung by means of an aerosol, liquid or powder for insufflation.
- either solid or fluid unit dosage forms can be prepared.
- the compound of Formula la is mixed with conventional ingredients such as talc, magnesium stearate, dicalcium phosphate, magnesium aluminum silicate, calcium sulfate, starch, lactose, acacia, methylcellulose, and functionally similar materials as pharmaceutical diluents or carriers.
- Capsules are prepared by mixing the compound with an inert pharmaceutical diluent and filling the mixture into a hard gelatin capsule of appropriate size.
- Soft gelatin capsules are prepared by machine encapsulation of a slurry of the compound with an acceptable vegetable oil, light liquid petrolatum or other inert oil.
- Fluid unit dosage forms for oral administration such as syrups, elixirs, and suspensions can be prepared.
- the water-soluble forms can be dissolved in an aqueous vehicle together with sugar, aromatic flavoring agents and preservatives to form a syrup.
- An elixir is prepared by using a hydro-alcoholic (ethanol) vehicle with suitable sweetners such as sugar and saccharin, together with an aromatic flavoring agent.
- Suspensions can be prepared with an aqueous vehicle with the aid of a suspensing agent such as acacia, tragacanth, methylcellulose and the like.
- a suspensing agent such as acacia, tragacanth, methylcellulose and the like.
- fluid unit dosage forms are prepared utilizing the compound and a sterile vehicle, water being preferred.
- the compound depending on the vehicle and concentration used, can be either suspended or dissolved in the vehicle.
- preparteral suspensions are prepared in substantially the same manner except that the compound is suspended in the vehicle instead of being dissolved and sterilization cannot be accomplished by filtration.
- the compound can be sterilized by exposure to ethylene oxide before suspending in the sterile vehicle.
- a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound.
- compositions are those adapted for in-- halation into the lung and containing a compound of the invention which is water-soluble.
- compositions for inhalation are of three basic types; (1 a powder mixture preferably micro-pulverized; (2) an aqueous solution to be sprayed with a nebulizer; and (3) an aerosol with volatile propellant in a pressurized container.
- the powders are quite simply prepared by mixing a compound of the formula with a solid base which is compatible with lung tissue, preferably lactose.
- the powders are packaged in a device adapted to emit a measured amount of powder when inhaled through the mouth.
- Aqueous solutions are prepared by dissolving the compound of the formula la in water and adding salt to provide an isotonic solution and buffering to a pH compatible with inhalation.
- the solutions are dispersed in a spray device or nebulizer and sprayed into the mouth while inhaling.
- Aerosols are prepared by dissolving a compound of the Formula la in water or ethanol and mixing with a volatile propellant and placing in a pressurized container having a metering valve to release a predetermined amount of material.
- the liquefied propellant employed is one which has a boiling point below 65F. at atmospheric pressure.
- the liquefied propellant should be nontoxic.
- suitable liquefied propellants which may be employed are the lower alkanes containing up to five carbon atoms, such as butane and pentane, or a lower alkyl chloride, such as methyl, ethyl, or propyl chlorides.
- fluorinated and fluorochlorinated lower alkanes such as are sold under the trademarks Freon and Genetron. Mixtures of the above-mentioned propellants may suitably be employed.
- Example of these propellants are dichlorodifluoromethane (Freon l2), dichlorotetrafluorethane (Freon 114), trichloromonofluoromethane (Freon ll”), dichloromonofluoromethane (Freon 2i monochlorodifluoromethane (Freon 22), trichlorotrifluoroethane (Freon ll3), difluoroethane (Genetron 142-A) and monochlorotrifluoromethane (Freon 13).
- unit dosage form refers to physically discrete units suitable as unitary dosages for human subjects and animals, each unit containing a predetermined quantity of active material calculated to produce the desired thera Guideic effect in association with the required pharmaceutical diluent, carrier or vehicle.
- the specifications for the novel unit dosage forms of this invention are dictated by and directly dependent on (a) the unique characteristics of the active material and the particular effect to be achieved and (b) the: limitations inherent in the art of compounding such an active material for use in humans and animals, as disclosed in detail in this specification, these being features of the present invention.
- suitable unit dosage forms in accord with this invention are tablets, capsules, pills, suppositories, powder packets, wafers, granules, cachets, teaspoonfuls, tablespoonfuls, dropperfuls, ampuls, vials, aerosols with metered discharges, segregated multiples of any of the foregoing, and other forms as herein described.
- An effective but non-toxic quantity of the compound is employed in treatment.
- the dosage of the compound for treatment depends on the route of administration.
- a dosage schedule of from about 0.01 to 50 mg. in a single dose administered parenterally or by inhalation embraces the effective range for preventing allergic attack for which the compositions are effective. More specifically, the single dose is from about 0.5 to about l'O mg. of compound.
- the oral dose is from about 0.1 to about 500 mg. in a single dose. More specifically, the single oral dose is from about l to about 50 mg. of compound.
- the dosage to be administered is repeated up to four times daily.
- compositions of the present invention provide a method for the prophylactic treatment of allergy or all anaphylactic reactions of a reagin or a non-reagin mediated nature. That is to say, these compositions when administered to a sensitized individual prior to the time that the individual comes into contact with substances (antigens) to which he is allergic, will prevent the allergic reaction which would otherwise occur.
- the process can be used for prophylactic treatment of such chronic conditions as bronchial asthma, allergic rhinitis, food allergy, hay fever, urticaria, auto-immune diseases, exercise induced asthma, stress induced asthma, and bird fanciers disease.
- Example 3 A lot of l0,000 tablets, each containing 50 mg. of dimethyl 1,1 ',4,4 '-tetrahy
- Example 4 One thousand two-piece hard gelatin capsules, each containing 50 mg. of dimethyl 1,1, 4,4'-tetrahydro- 4,4-dioxo[6,6'-biquinoline]-2,2'-dicarboxylate are prepared from the following types and amounts of ingredients:
- the ingredients are mixed well and filled into capsules of the proper size.
- Capsules so prepared are useful in preventing attacks of bronchial asthma at a dose of one capsule every 4 to 6 hours.
- Example 5 One thousand tablets, each containing 50 mg. of dimethyl 1,1, 4,4'-tetrahydro-4,4-dioxo[6,6- biquinoline]-2,2'-bicarboxylate are made from the following types and amounts of ingredients:
- the ingredients are screened and blended together and pressed into 575 mg. tablets.
- the tablets are useful to protect against food allergy at a dose of 1 tablet before meals.
- Example 6 A sterile prepartion suitable for intramuscular injection and containing 1 mg. of dimethyl 1,1, 4,4- tetrahydro-4,4-diox0[6,6'-biquinoline]-2,2'- dicarboxylate in each milliliter is prepared from the following ingredients:
- One milliliter of this sterile preparation is injected for prophylactic treatment of allergic rhinitis.
- Example 8 A powder mixture consisting of 1.0 Gm. of tris(hydroxymethyl)aminomethane salt of l,l,4,4-tetrahydro- 4,4' dioxo[6,6-biquinoline]-2,2-dicarboxylic acid and sufficient lactose to make 5 grams of mixture is micropulverized and placed in an insufflator designed to deliver mg. of powder per dose.
- the powder is inhaled into the lungs for prevention of asthmatic attacks.
- Example 9 Twelve grams of an aerosol composition is prepared from the following ingredients:
- the THAM salt is dissolved in the ethanol and chilled to 30C. and added to the chilled Freons.
- the 12 grams of composition is added to a 13 cc. plastic coated bottle and capped with a metering valve. The metering valve releases mg. of composition in an aerosol.
- the aerosol is inhaled every 4 to 6 hours for prevention of asthmatic attacks.
- Example 10 After allowing for the differing solubilities of the compounds and the activity of the particular compound as measured by the in vivo rat passive cutaneous anaphylaxis reaction, a suitable quantity of each of the compounds of Table ll, 111 and IV are substituted for the active compound in the compositions and uses of Examples 3 to 9. Results showing anti-allergy activity are obtained.
- R is selected from the group consisting of hydrogen, alkyl from one to three carbon atoms, inclusive, phenyl, alkali metal or a pharmaceutically acceptable amine salt;
- Z is selected from the group consisting of hydrogen, alkyl from one to three carbon atoms, inclusive, and phenyl;
- X and Y are the same or different monosubstituents, and when X and Y are the same monosubstituent, it is selected from the group consisting of hydrogen, halogen, alkyl from one to three carbon atoms, inclusive, alkoxy from one to three carbons inclulsive, phenyl, nitro, trifluoromethyl, cyano and o I c -o where Q is selected from the group consisting of hydrogen alkyl from one to three carbon atoms, inclusive; phenyl, an alkali metal and a pharmaceutically acceptable amine salt, with the proviso that where R is hydrogen, alkali metal or an amine salt, then Q must be the same as R; with the further provision that when a.
- X is at the position, Y is at the 5 or 7 position, b.
- X is at the 7 position, Y is at the 5 or 7 position c.
- X is at the 8 position, Y is at the 8' position and when X and Y are different, one monosubstituent must be hydrogen and the other monosubstituent is selected from the above group and can be located anywhere on the ring.
- R is selected from the group consisting of hydrogen, alkali metal and a pharmaceutically acceptable amine salt
- X and Y are the same or different monosubstituents, and when X and Y are the same monosubstituent, it is selected from the group consisting of hydrogen, alkyl from one to three carbon atoms, inclusive; alkoxy from one to three carbon atoms, inclusive; halogen, cyano, and
- Q is selected from the group consisting of hydrogen, alkali metal and a pharmaceutically acceptable amine salt, with the proviso that Q is the same as R; and when X and Y are different, one monosubstituent is hydrogen and the other monosubstituent is selected from the above group.
- R is an alkali metal or a pharmaceutically acceptable amine salt
- X and Y are the same or different monosubstituents and when X and Y are the same monosubstituent, it is selected from the group consisting of hydrogen, fluoro, chloro, methyl, ethyl, methoxy, ethoxy, cyano and where Q is selected from the group consisting of alkali metal and a pharmaceutically acceptable amine salt with the proviso that Q is the same as R, and when X and Y are different, one monosubstituent is hydrogen and the other monosubstituent is selected from the above group.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Coupounds of formula
ARE USEFUL IN THE PROPHYLACTIC TREATMENT OF SENSITIZED HUMAN AND ANIMALS FOR ALLERGY AND ALL ANAPHYLACTIC REACTIONS OF A REAGIN OR NON-REAGIN MEDIATED NATURE. The compounds are formulated with pharmaceutical carriers for oral, parenteral, or insufflation means of administration.
ARE USEFUL IN THE PROPHYLACTIC TREATMENT OF SENSITIZED HUMAN AND ANIMALS FOR ALLERGY AND ALL ANAPHYLACTIC REACTIONS OF A REAGIN OR NON-REAGIN MEDIATED NATURE. The compounds are formulated with pharmaceutical carriers for oral, parenteral, or insufflation means of administration.
Description
United States Patent 1 Hall et al.
1 1,1',4,4'-TETRAnYnRo-4,4'.
D10X0(6,6BlQUINOLINE)-2,2'. DICARBOXYLATES [75] Inventors: Charles M. Hall; Herbert G.
Johnson, both of Kalamazoo, Mich.
[73] Assignee: The Upjohn Company, Kalamazoo,
Mich.
[22] Filed: June 9, 1972 [21] Appl. No.: 261,524
[52] US. Cl..... 260/286 R, 260/268 R, 260/283 Bl, 260/283 SY, 260/283 CN, 260/286 R,
{51] int. Cl C07d 33/46 [58] Field of Search. 260/283 Bl, 345.2, 286 R,287
[56] References Cited FOREIGN PATENTS OR APPLICATIONS 2,145,423 3/1972 Germany 260/283 Bl 2,130,408 12/1971 Germany .1 260/287 [451 Feb. 11, 1975 Primary E.\'aminer-Donald G. Daus Attorney, Agent, or Firm-Martin B. Barancik; Roman Saliwanchik [57] ABSTRAQT Coupounds of formula 6 Claims, No Drawings 1 2 1,1 ',4,4-TETRAHYDRO-4,4'- lected from the above groups and can be located any- DIOXO(6,6'BIQUINOLINE)-2,2 where on the ring.
DICARBOXYLATES The preferred compounds are those compounds where R is selected from the group consisting of hydro- 5 gen, alkali metal and an amine salt; Z is hydrogen. X
BRIEF SUMMARY OF THE INVENTION and Y can be the same or different monosubstituents.
We have discovered that novel compounds of For- When X and Y are the same monosubstituentQthey are mula Ia are useful in the prophylactic treatment of senselected from the group consisting of hydrogen. alkyl sitized humans and animals for allergy and all anaphyfrom one to three carbon atoms, inclusive, alkoxy from lactic reactions ofa reagin or non-reagin mediated naone to three carbon atoms, inclusive. halogen. cyano, ture. The compounds are formulated with pharmaceuand tical carriers for oral, parenteral, or insufflation means 0 of administration. C 0.
. wherein Q is selected from the group consisting of hy- DETAILED DESCRIPTION OF THE INVENTION l5 drogen, alkali metal and an amine salt, with the proviso In accordance with this invention, we provide comthat Q is the same as R; and with the same aforemenpounds represented by structure la tioned restriction on the location of the monosubstitu- OR la wherein it is understood that la can exist in its tautoents. When X and Y are different, one monosubstituent meric form lb and that the compounds of this invention is hydrogen and the other monosubstituent is selected are likely to be mixtures of all tautomeric forms, the from the more preferred group and can be located anypercentages of each tautomer to be at least partially dewhere on the ring. pendent on the nature of R, X, Y, and Z, and the physi- The more preferred compounds are those comcal environment of the compound. pounds where R is an alkali metal or an amine salt and lb C OR For the purpose ofb revity throughout the application Z is hydrogen. X and Y can be the same or different and appended claims, the compounds will be referred monosubstituents. When X and Y are the monosubto hereinafter in their keto form, structure Ia; stituent, they are selected from the group consisting of The R substituent is selected from the group consisthydrogen, fluoro, chloro, methyl, ethyl, methoxy, ething of hydrogen, alkyl from one to three carbon atoms, oxy, cyano, and inclusive, phenyl, alkali metal or an amine salt.
Z is selected from the group consisting of hydrogen, -&
. alkyl from one to three carbon atoms, inclusive, and p y where Q is selected from the group consisting of alkali X and Y can he thg Same or d'ffereht mohosuhsmu metal and an amine salt with the proviso that Z is the chm when X and Y are the same mohosubsmuem 5 same as R, with the aforementioned restrictions on the h are Selected from the group consisting of hydra location of the monosubstituent; and when X and Y are g halogen alkyl from one to three carbon atoms different, one monosubstituent is hydrogen and the Cluslve, alkoxy having from one t0 three carbon atoms other monosubstituent is selected from the more preihclusive, Phehyh trifluommethyh cyaho and ferred group and can be located anywhere on the ring. 2 m As employed in the above disclosure and throughout the specification, the term halogen includes fluoro, where Q is selected from the group consisting of hydrochloro, bromo, and iodo and the term alkyl includes gen; alkyl from one to three carbon atoms, inclusive; methyl, ethyl, propyl, and isopropyl when limited to phenyl; an alkali metal and an amine salt, with the prothree carbon atoms. Alkali metal includes sodium viso that where R is hydrogen, alkali metal or an amine and potassium. The term amine salt" includes all salt, when Q must be the same as R; with the further pharmaceutically acceptable amine salts of the invenprovision that when tion, including, for example, the amines ammonia, trisa. X is at the 5 position, Y is at the 5' or 7' position, (hydroxymethyl)-aminomethane, D-threo-2-aminolb. X is at the 7 position, Y is at the 5 or 7' position, p-nitrophenyl-l ,3-propanediol, N,N- c. X is at the 8 position, Y is at the 8 position; his(hydroxycthyl)piperazine, 2-amino-2-methyl-land when X and Y are different, one monosubstituent propanol, 2-mnino-2-methyl-l ,3-propanediol and 2,2-
must be hydrogen and the other monosubstituent is sehis(hydroxymethyl)-2,2',2"-nitriolotriethanol and fur- 3 ther amines including H NR, NHR and NR wherein R is selected from the group consisting of alkyl from one to three carbon atoms, inclusive, and -CH CH OH.
The compounds of this invention can be prepared by methods known to the art. The basic synthetic pathway employed is the reaction of an appropriately substituted benzidine (II) with an oxaloacetate sodium salt (III) in the presence of a solvent to form the diadduct (IV). The R group is limited to the alkyl group of from one to three carbon atoms, inclusive; and phenyl. Ring closure to the desired compound (la) is accomplished by heating the diadduct at appropriate conditions.
4 vention. Included among starting materials made available in the art are the following substituted benzidine compounds:
TAB LE I NHg O Y O l Z C-OR R-C\ \I c-z C H I ll x N4: C C-0R After the above synthesis has been carried out, the X Y carboxylate can be transesterified to other esters or hy- H H drolyzed to the carboxy acid. The carboxy acid is con- 2 Br H verted to the alkali metal or amine salts by standard 59 3 methods. 3 I H It should be noted that because of the symmetry in S the benzidine starting material, a monosubstituent at 3 CH H the 2 position is equivalent to a monosubstituent at the gg 6 position, 2' position or 6' position. When the mono- 3 Cl H substituent is at the 3 position, equivalent positions are g at 5, 3' and 5. However, when the diadduct is heated, 3 OCi-L, H the ring is closed and a portion of the symmetry is lost. 3 Consequently, for every starting material substituted at 2 I H the 2 and 2 position, three different compounds of this invention are prepared. Referring to structure la, these 3 Cl 3'c1 compounds are the 5 5, 5 7, and 7 7' disubstituted ZP P 1,1, 4,4-tetrahydro-4,4'-dioxo[6,6'-biquinoline]-2,2'- 3 0iC H 3OiC,,H dicarboxylic acid. For example, when the starting ma- 2 terial 2,2-dimethyl benzidine is reacted with diethyl 2CH.'; ZICH, 1 sodium oxaloacetate, the compounds of the invention are diethyl 5,5'-dimethyl-l 4,4'-tetrahydro-4,4'- 3 Br 3'Br dioxo[6,6-biquinoline]-2,2'-dicarboxylate, diethyl gg gig 5,7-dimethyl-l,l 4,4'-tetrahydro-4,4-dioxo[6,6- 2 N0 2'NO biquinoline]-2,2'-dicarboxylate, and diethyl 7,7- 2 F dimethyl-l ,l 4,4-tetrahydro-4,4-dioxo[6,6- biquinoline]-2,2'-dicarboxylate.
When the starting material is substituted at the 3 position, only one compound of the invention is prepared, the monosubstitution at the 8 position.
X and Y substituted benzidines where X and Y are the same monosubstituent or where either X orY is hydrogen, have been prepared in the art prior to this inexample, trifluoromethyl benzidine is prepared by reacting sulfur tetrafluoride with carboxy-paradinitrobiphenyl followed by reduction to the benzine starting compound. The carboxyamide is prepared by reacting the carboxy-para-dinitrobiphenyl with thionyl chloride followed by ammonia treatment to give the carboxyamide-para-dinitrobiphenyl This compound is then readily reduced by either of the methods described above to the corresponding benzidine compound. Furthermore, cyanobenzidine is prepared by reacting carboxyamide-para-dinitrobiphenyl with titanium tetrachloride in tetrahydrofuran and base at 0 C. to give the cyano-para-dinitrobiphenyl compound which is readily reduced by either of the methods disclosed above to the cyanobenzidine.
The second reactant, the oxaloacetate derivative is also readily available. Compounds where R is ethyl and Z is hydrogen, methyl, ethyl or phenyl are known in the art.
Where Z is hydrogen, an alternative reagent to the oxaloacetate derivative is available to form the diadduct. Acetylene dicarboxylate (V), where R is limited to alkyl of from one to three carbon atoms, inclusive, or phenyl, can be added to the substituted benzidine to form the diadduct (IV) as illustrated below:
ll g ROC-CC- 0R MHz In the formation of the diadduct and subsequent ring closure, the following processing conditions can be observed.
When using the oxaloacetate reagent to form the diadduct, there should be a sufficient amount of acid present to protonate the oxaloacetate carbanion and catalyze the removal of the keto grouping as water. The acid can also serve as a solvent for the two reagents as well. For example, glacial acetic acid, propionic acid, p-toluene sulfonic acid, and butyric acid are acids which can be used. lf a further reagent is needed to place the two reactants into solution, (or a cosolvent desired), benzene, toluene, diethyl ether, dioxane, tetrahydrofuran, or alcohols from one to about four carbon atoms can be employed. The length of time for the formation of the diadduct is temperature dependent.
At room temperature the reaction proceeds rather slowly but as the temperature is raised, reaction time is decreased. Acceptable reaction times are achieved at temperatures ranging from about 40 to about (7.. although reaction temperatures can be above C. if desired.
With regard to the use ofthe acetylene dicarboxylate reactant, in the formulation of the diadduct, appropriate solvents are alcohols having from one to about six carbon atoms. preferably one to about three carbon atoms, benzene, diethylether, dioxane, tetrahydrofuran, or any other solvent which places both of the reactants in solution and allows the desired compound to form. Generally the reaction proceeds readily at room temperature and can be promoted by an increase in temperature to about 100 C.
Ring closure of the diadduct, prepared by the methods disclosed above, and formation of the desired compound can be accomplished by heating the diadduct at a relatively high temperature. This heating can be done to the neat diadduct. However, it is preferred to use a solvent which can function as a heat transfer medium. Any high boiling inert solvent such as a mineral oil, hexamethylphosphoric triamide, diphenyl ether, or Dowtherm A, which appears to be primarily a diphenyl ether side product of the Dow Chemical Company preparation of phenol, is suitable. The ring cyclization step is preferably carried outlat temperatures of from about 220 C. to about 280 (3., although lower or higher temperatures can be employed ifdesired. Particularly preferred solvents are Dowtherm A, or diphenyl ether, which boil at about 250 C., thus enabling the ring cyclization to occur during reflux.
An additional advantage of the elevated temperature during the ring cyclization step is that any adduct formed in the preceding step which is not in a position to cyclize since it is trans to the benzene ring is isomerized to the cis configuration during the heating, thereby allowing substantial yields of the desired compound to be produced. This trans adduct preparation occurs more frequently when an aprotic solvent and acetylene dicarboxylate are used in the adduct formation step. As stated previously, at this point various esters, the acid, or salts can be prepared at the R position of the carboxy group. Different esters can be prepared by a standard transesterification reaction. Ester groups are converted to the acid by treatment with base and acid. The acid can then be easily converted to an amine salt or alkali metal by contacting the diacid with two equivalents of the desired amine or alkali metal and heating in-a sufficient amount of water to effect solubilization. The crystalline salts can be precipitated by the addition of methanol. When R is hydrogen, alkali metal or amine. and X or Y is then Q is the same as R.
Following is an illustrative list of starting materials and desired compounds which can be prepared by the above disclosed procedures. It is to be understood that the Table I] X and Y monosubstituents are at the designated position of the starting material and that the final compounds have isomeric structures as previously explained.
TABLE n .SLlLLLLlQ Mei ll ll I ll RO-CC-C-C-OR whe re Z=H The above illustrative examples of Table ll are prepared where Z in the oxaloacetate sodium salt is methyl, ethyl, pro'pyl, isopropyl, or phenyl.
TABLE IV Example 1 1,1, 4,4'-tetrahydro-4,4-diox0[6,6'-biquinoline]-2,2'- dicarboxylic acid Thirty grams of dimethyl acetylenedicarboxylate is added dropwise to a solution of I84 grams of benzidine in 500 ml. of methanolat 0 C. The reaction mix- 'ture is stirred at 0 C. for 30 minutes and at room temperature for l6 hours. The crystalline product is collected by filtration. Recrystallization gives yellow needles melting at l36-l38 C. 3.0 Gram of the above solid was dissolved in IQ ml. of Dowtherm A and heated at 250 C. for 5 minutes, during which time a yellow solid precipitates. 2.2 Grams of the yellow solid is refluxed in aqueous 5% NaOH solution for 1 hour. The reaction mixture is cooled and acidified with concentrated HCl to pH 4. The resulting light yellow acid is collected by filtration.
Example 2 Disodium-l l ',-4,4'-tetrahydro-4,4'-dioxo-[6,6- biquinoline]-2,2-dicarboxylate The acid'prepared in Example 1 is converted to its sodium salt by treatment with an approximately halfsaturated, hot solution of NaHCO The disodium salt precipitates upon cooling. Recrystallization from water gives the disodium compound as its trihydrate.
Anal. Calcd: for: C H O N JH O:
C, 50.64; H, 3.40; N, 5.91. Found: C, 50.24; H, 2.99; N, 5.94.
The compositions of the present invention are presented for administration to humans and animals in unit dosage forms, such as tablets, capsules, pills, powders, granules, sterile parenteral solutions or suspensions, and oral solutions or suspensions, and oil-in-water and water-inoil emulsions containing suitable quantities of the compound of Formula la. The preferred method of administration is by inhalation into the lung by means of an aerosol, liquid or powder for insufflation.
For oral administration either solid or fluid unit dosage forms can be prepared. For preparing solid compositions such as tablets, the compound of Formula la is mixed with conventional ingredients such as talc, magnesium stearate, dicalcium phosphate, magnesium aluminum silicate, calcium sulfate, starch, lactose, acacia, methylcellulose, and functionally similar materials as pharmaceutical diluents or carriers. Capsules are prepared by mixing the compound with an inert pharmaceutical diluent and filling the mixture into a hard gelatin capsule of appropriate size. Soft gelatin capsules are prepared by machine encapsulation of a slurry of the compound with an acceptable vegetable oil, light liquid petrolatum or other inert oil.
Fluid unit dosage forms for oral administration such as syrups, elixirs, and suspensions can be prepared. The water-soluble forms can be dissolved in an aqueous vehicle together with sugar, aromatic flavoring agents and preservatives to form a syrup. An elixir is prepared by using a hydro-alcoholic (ethanol) vehicle with suitable sweetners such as sugar and saccharin, together with an aromatic flavoring agent.
Suspensions can be prepared with an aqueous vehicle with the aid ofa suspensing agent such as acacia, tragacanth, methylcellulose and the like.
For parenteral administration, fluid unit dosage forms are prepared utilizing the compound and a sterile vehicle, water being preferred. The compound, depending on the vehicle and concentration used, can be either suspended or dissolved in the vehicle. In preparteral suspensions are prepared in substantially the same manner except that the compound is suspended in the vehicle instead of being dissolved and sterilization cannot be accomplished by filtration. The compound can be sterilized by exposure to ethylene oxide before suspending in the sterile vehicle. Advantageously, a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound.
The preferred compositions are those adapted for in-- halation into the lung and containing a compound of the invention which is water-soluble.
Compositions for inhalation are of three basic types; (1 a powder mixture preferably micro-pulverized; (2) an aqueous solution to be sprayed with a nebulizer; and (3) an aerosol with volatile propellant in a pressurized container.
The powders are quite simply prepared by mixing a compound of the formula with a solid base which is compatible with lung tissue, preferably lactose. The powders are packaged in a device adapted to emit a measured amount of powder when inhaled through the mouth.
Aqueous solutions are prepared by dissolving the compound of the formula la in water and adding salt to provide an isotonic solution and buffering to a pH compatible with inhalation. The solutions are dispersed in a spray device or nebulizer and sprayed into the mouth while inhaling.
Aerosols are prepared by dissolving a compound of the Formula la in water or ethanol and mixing with a volatile propellant and placing in a pressurized container having a metering valve to release a predetermined amount of material.
The liquefied propellant employed is one which has a boiling point below 65F. at atmospheric pressure. For use in compositions intended to produce aerosols for medicinal use, the liquefied propellant should be nontoxic. Among the suitable liquefied propellants which may be employed are the lower alkanes containing up to five carbon atoms, such as butane and pentane, or a lower alkyl chloride, such as methyl, ethyl, or propyl chlorides. Further suitable liquefied propellants are the fluorinated and fluorochlorinated lower alkanes such as are sold under the trademarks Freon and Genetron. Mixtures of the above-mentioned propellants may suitably be employed. Example of these propellants are dichlorodifluoromethane (Freon l2), dichlorotetrafluorethane (Freon 114), trichloromonofluoromethane (Freon ll"), dichloromonofluoromethane (Freon 2i monochlorodifluoromethane (Freon 22), trichlorotrifluoroethane (Freon ll3), difluoroethane (Genetron 142-A) and monochlorotrifluoromethane (Freon 13).
The term unit dosage form, as used in the specification and claims, refers to physically discrete units suitable as unitary dosages for human subjects and animals, each unit containing a predetermined quantity of active material calculated to produce the desired thera peutic effect in association with the required pharmaceutical diluent, carrier or vehicle. The specifications for the novel unit dosage forms of this invention are dictated by and directly dependent on (a) the unique characteristics of the active material and the particular effect to be achieved and (b) the: limitations inherent in the art of compounding such an active material for use in humans and animals, as disclosed in detail in this specification, these being features of the present invention. Examples of suitable unit dosage forms in accord with this invention are tablets, capsules, pills, suppositories, powder packets, wafers, granules, cachets, teaspoonfuls, tablespoonfuls, dropperfuls, ampuls, vials, aerosols with metered discharges, segregated multiples of any of the foregoing, and other forms as herein described. An effective but non-toxic quantity of the compound is employed in treatment.
The dosage of the compound for treatment depends on the route of administration. A dosage schedule of from about 0.01 to 50 mg. in a single dose administered parenterally or by inhalation embraces the effective range for preventing allergic attack for which the compositions are effective. More specifically, the single dose is from about 0.5 to about l'O mg. of compound. The oral dose is from about 0.1 to about 500 mg. in a single dose. More specifically, the single oral dose is from about l to about 50 mg. of compound. The dosage to be administered is repeated up to four times daily.
The administration of the compositions of the present invention to humans and animals provides a method for the prophylactic treatment of allergy or all anaphylactic reactions of a reagin or a non-reagin mediated nature. That is to say, these compositions when administered to a sensitized individual prior to the time that the individual comes into contact with substances (antigens) to which he is allergic, will prevent the allergic reaction which would otherwise occur.
For example, the process can be used for prophylactic treatment of such chronic conditions as bronchial asthma, allergic rhinitis, food allergy, hay fever, urticaria, auto-immune diseases, exercise induced asthma, stress induced asthma, and bird fanciers disease.
Example 3 A lot of l0,000 tablets, each containing 50 mg. of dimethyl 1,1 ',4,4 '-tetrahy|dro-4,4'-dioxo[6,6- biquinoline]-2,2'-dicarboxylate is prepared from the following types and amount of ingredients:
Dimethyl l,l ',4,4'-tetrahydro-4,4'-
dioxo[ 6,6 '-biquinoline 2,2-dicarboxylate 500 Gm. Dicalcium phosphate 1,000 Gm. Methylcellulose, U.S.P. (l5 cps) 6O Gm. Talc I50 Gm. Corn Starch 200 Gm. Calcium stearate l2 Gm.
1 1 Example 4 One thousand two-piece hard gelatin capsules, each containing 50 mg. of dimethyl 1,1, 4,4'-tetrahydro- 4,4-dioxo[6,6'-biquinoline]-2,2'-dicarboxylate are prepared from the following types and amounts of ingredients:
Dimethyl 1,1 4,4'-tetrahydro-4.4'-
dioxo[6,6'-biquinoline]-2,2-
dicarboxylate 50 Gm. Talc 150 Gm. Magnesium stearate l Gm.
The ingredients are mixed well and filled into capsules of the proper size.
Capsules so prepared are useful in preventing attacks of bronchial asthma at a dose of one capsule every 4 to 6 hours.
Example 5 One thousand tablets, each containing 50 mg. of dimethyl 1,1, 4,4'-tetrahydro-4,4-dioxo[6,6- biquinoline]-2,2'-bicarboxylate are made from the following types and amounts of ingredients:
Dimethyl l, l 4,4'-tetrahydro- 4,4-dioxo[6,6'-biquinoline]- 2,2-dicarboxylate 50 Gm. Microcrystalline cellulose NF 420 Gm. Starch 100 Gm. Magnesium stearate powder 5 Gm.
The ingredients are screened and blended together and pressed into 575 mg. tablets.
The tablets are useful to protect against food allergy at a dose of 1 tablet before meals.
Example 6 A sterile prepartion suitable for intramuscular injection and containing 1 mg. of dimethyl 1,1, 4,4- tetrahydro-4,4-diox0[6,6'-biquinoline]-2,2'- dicarboxylate in each milliliter is prepared from the following ingredients:
2.2'-dicarboxylate l Gm. Benzyl benzoate 200 ml. Methylparaben 1.5 Gm. Propylparaben 0.5 Gm. Cottonseed oil q.s. 1,000. ml.
One milliliter of this sterile preparation is injected for prophylactic treatment of allergic rhinitis.
Example 8 A powder mixture consisting of 1.0 Gm. of tris(hydroxymethyl)aminomethane salt of l,l,4,4-tetrahydro- 4,4' dioxo[6,6-biquinoline]-2,2-dicarboxylic acid and sufficient lactose to make 5 grams of mixture is micropulverized and placed in an insufflator designed to deliver mg. of powder per dose.
The powder is inhaled into the lungs for prevention of asthmatic attacks.
Example 9 Twelve grams of an aerosol composition is prepared from the following ingredients:
Tris( hydroxymethyl )aminomethane salt of l,l'.4,4'-tetrahydro- 4.4'-dioxo[6,6'-biquinolinel- 2.2'-dicarboxylate acid 0.25 Gm. Absolute ethanol 4.620 Gm. Freon 12 1.43 Gm. Freon 114 5.70 Gm.
The THAM salt is dissolved in the ethanol and chilled to 30C. and added to the chilled Freons. The 12 grams of composition is added to a 13 cc. plastic coated bottle and capped with a metering valve. The metering valve releases mg. of composition in an aerosol.
The aerosol is inhaled every 4 to 6 hours for prevention of asthmatic attacks.
Example 10 After allowing for the differing solubilities of the compounds and the activity of the particular compound as measured by the in vivo rat passive cutaneous anaphylaxis reaction, a suitable quantity of each of the compounds of Table ll, 111 and IV are substituted for the active compound in the compositions and uses of Examples 3 to 9. Results showing anti-allergy activity are obtained.
We claim: 1. A compound of the formula Example 7 Six hundred ml. of an aqueous solution containing 1.0 mg. of the tris(hydroxymethyl)aminomethane (THAM) salt of 1,1,4,4'-tetrahydro-4,4'-dioxo[6,6-
wherein R is selected from the group consisting of hydrogen, alkyl from one to three carbon atoms, inclusive, phenyl, alkali metal or a pharmaceutically acceptable amine salt;
Z is selected from the group consisting of hydrogen, alkyl from one to three carbon atoms, inclusive, and phenyl;
X and Y are the same or different monosubstituents, and when X and Y are the same monosubstituent, it is selected from the group consisting of hydrogen, halogen, alkyl from one to three carbon atoms, inclusive, alkoxy from one to three carbons inclulsive, phenyl, nitro, trifluoromethyl, cyano and o I c -o where Q is selected from the group consisting of hydrogen alkyl from one to three carbon atoms, inclusive; phenyl, an alkali metal and a pharmaceutically acceptable amine salt, with the proviso that where R is hydrogen, alkali metal or an amine salt, then Q must be the same as R; with the further provision that when a. X is at the position, Y is at the 5 or 7 position, b. X is at the 7 position, Y is at the 5 or 7 position c. X is at the 8 position, Y is at the 8' position and when X and Y are different, one monosubstituent must be hydrogen and the other monosubstituent is selected from the above group and can be located anywhere on the ring.
2. A compound in accordance with claim 1 wherein R is selected from the group consisting of hydrogen, alkali metal and a pharmaceutically acceptable amine salt;
Z is hydrogen;
X and Y are the same or different monosubstituents, and when X and Y are the same monosubstituent, it is selected from the group consisting of hydrogen, alkyl from one to three carbon atoms, inclusive; alkoxy from one to three carbon atoms, inclusive; halogen, cyano, and
wherein Q is selected from the group consisting of hydrogen, alkali metal and a pharmaceutically acceptable amine salt, with the proviso that Q is the same as R; and when X and Y are different, one monosubstituent is hydrogen and the other monosubstituent is selected from the above group.
3. A compound in accordance with claim I wherein R is an alkali metal or a pharmaceutically acceptable amine salt;
Z is hydrogen;
X and Y are the same or different monosubstituents and when X and Y are the same monosubstituent, it is selected from the group consisting of hydrogen, fluoro, chloro, methyl, ethyl, methoxy, ethoxy, cyano and where Q is selected from the group consisting of alkali metal and a pharmaceutically acceptable amine salt with the proviso that Q is the same as R, and when X and Y are different, one monosubstituent is hydrogen and the other monosubstituent is selected from the above group.
4. l,l 4,4-tetrahydro-4,4'-dioxo[6,6'-biquinoline]- 2,2-dicarboxylate acid according to claim 1.
5. Disodium l,l 4,4-tetrahy'dro-4,4-dioxo[6,6- biquinoline]-2,2-dicarboxylate according to claim 1.
6. Di(tris-hydroxymethyl)ammonium l,l ,4,4- tetrahydro-4,4-dioxo[6,6-biquinoline]-2,2-
dicarboxylate according to claim 1.
UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION PATENT NO. 3,865,831 Page 1 of 2 DATED February 11, 1975 vE T0R(5) Char1es M. Ha11 and Herbert G. I Johnson It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:
Front Page; change references to inc1ude "U.S. Patents Cited" and "Other References" I U.S. Patents 2,499,661 3/1950 Marc1'1hacy 260-286R 2,760,964 8/1956 Carrington 260-286R 3,519,652 7/1970 P1 112 Maurice 260-3452 3,660,084 5/1972 VanHeerton et a1 260-28381 3,673,218 6/1972 Cairns et a1 260-345R Other References Mentzer et a1. Chem. Abstr. V01. 38 C01. 6337 (1944) Sardesai et a1. Chem. Abstr. V01. 55 C01. 22313h (1961) Siveramakrishnan et a1. Chem. Abstr. V01. 56 C01; 2419-20 Throughout the patent, change 1'ta11'c1'zed "Ia" to --Ia--. Co1umn 2, 11'nes 41-2; change "the monosubstituents" to --the same m0nosubst1'tuents--.
Co1umn 3, 11'ne 1; change "NHR' to --HNR' Co1umn 5, 11' ne 7; change "d1n1'tr0b1'pheny1" t0 --d1'n1'tr0b1'pheny1 Co1umn 6, 11'ne 8; change "formu1at1'on to --formation--.
Co1umn 6, 11ne 25; change "A" to '--A Co1umn 8, 11'ne 2; change "m1. of methano1" t0 --m1 methano1-- Co1umn 8, 11'ne 25; change "C H 0 N .3H 0" to --C H O N -3H O--.
Co1umn 8, 11ne 58; change "sweetners" to --sweeteners--.
UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION PATENT NO. 3,865,831 I Page 2 of 2 DATED February 11, 1975 INVENTOR(S) Charles M. Hall and Herbert G. Johnson It is certified that error appears in the above-identified patent and that said Letters Patent is hereby corrected as shown below:
Column 8, line 62; change "suspensing to -suspending--. Column 9, line 34; change "formula" to --Formula--.
Column 9, line 57; change "Example" to --Examples--. Column 10, line 57; change "(15 cps) 60 Gm." to
-- D 60 Gm.-.
Column 14, lines 1-3, change 0 to O Column 14 line 4; change "wherein" to --where-. Column 14, line 31; change "dicarboxylate to --d1carboxyl1'c--.
Signed and Scaled this Twenty-sixth Day of August I980 smu Attest:
SIDNEY A. DIAMOND Attesting Officer Commissioner of Patents and Trademarks
Claims (6)
1. A COMPOUND OF THE FORMULA
2. A compound in accordance with claim 1 wherein R is selected from the group consisting of hydrogen, alkali metal and a pharmaceutically acceptable amine salt; Z is hydrogen; X and Y are the same or different monosubstituents, and when X and Y are the same monosubstituent, it is selected from the group consisting of hydrogen, alkyl from one to three carbon atoms, inclusive; alkoxy from one to three carbon atoms, inclusive; halogen, cyano, and
3. A compound in accordance with claim 1 wherein R is an alkali metal or a pharmaceutically acceptable amine salt; Z is hydrogen; X and Y are the same or different monosubstituents and when X and Y are the same monosubstituent, it is selected from the group consisting of hydrogen, fluoro, chloro, methyl, ethyl, methoxy, ethoxy, cyano and
4. 1,1'', 4,4''-tetrahydro-4,4''-dioxo(6,6''-biquinoline)-2,2''-dicarboxylate acid according to claim 1.
5. Disodium 1,1'', 4,4''-tetrahydro-4,4''-dioxo(6,6''-biquinoline)-2,2''-dicarboxylate according to claim 1.
6. Di(tris-hydroxymethyl)ammonium 1,1'',4,4''-tetrahydro-4,4''-dioxo(6,6''-biquinoline)-2,2''-dicarboxylate according to claim 1.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US261524A US3865831A (en) | 1972-06-09 | 1972-06-09 | 1,1{40 ,4,4{40 -tetrahydro-4,4{40 -dioxo(6,6{40 biquinoline)-2,2{40 -dicarboxylates |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US261524A US3865831A (en) | 1972-06-09 | 1972-06-09 | 1,1{40 ,4,4{40 -tetrahydro-4,4{40 -dioxo(6,6{40 biquinoline)-2,2{40 -dicarboxylates |
Publications (1)
Publication Number | Publication Date |
---|---|
US3865831A true US3865831A (en) | 1975-02-11 |
Family
ID=22993694
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US261524A Expired - Lifetime US3865831A (en) | 1972-06-09 | 1972-06-09 | 1,1{40 ,4,4{40 -tetrahydro-4,4{40 -dioxo(6,6{40 biquinoline)-2,2{40 -dicarboxylates |
Country Status (1)
Country | Link |
---|---|
US (1) | US3865831A (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2130408A1 (en) * | 1970-06-19 | 1971-12-23 | Ici Ltd | Pharmaceutical compositions |
DE2145423A1 (en) * | 1970-09-28 | 1972-03-30 | Impe-al Chemical Industries Ltd., London | Quinoline derivatives |
-
1972
- 1972-06-09 US US261524A patent/US3865831A/en not_active Expired - Lifetime
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2130408A1 (en) * | 1970-06-19 | 1971-12-23 | Ici Ltd | Pharmaceutical compositions |
DE2145423A1 (en) * | 1970-09-28 | 1972-03-30 | Impe-al Chemical Industries Ltd., London | Quinoline derivatives |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0310950B1 (en) | Quinoline intermediates for the synthesis of 1H-imidazo[4,5-c]quinolines and 1H-imidazo[4,5-c]quinolin-4-amimes | |
CA1318675C (en) | Substituted 9-amino-tetrahydroacridines and related compounds, a process for their preparation and their use as medicaments | |
US3987192A (en) | Compositions and process of treatment | |
US4091011A (en) | 3-Cyano-oxanilic acid derivatives | |
US4128570A (en) | Anti-allergic oxanil compounds | |
US4181724A (en) | Quinoxalinone compounds useful for expanding the lumina or air passages in mammals | |
US3852324A (en) | N,n-(cyano-phenylene) dioxamic acids | |
US4089973A (en) | Cyano phenylene dioxamic acid compounds used in the treatment of allergy | |
US4150140A (en) | Benzothiazolyl oxanic acids, esters and salts | |
PL106659B1 (en) | HOW TO MAKE NEW DERIVATIVES OF PIRAZOLO / 1,5-C / CHINAZOLINE | |
US3836541A (en) | 3-cyano-2-pyrryl oxamic acids | |
US4066766A (en) | 1-Oxo-6-substituted pyrimido [1,2-a]quinoline-2-carboxylic acids and derivatives thereof and their use as antiallergy agents | |
US3865831A (en) | 1,1{40 ,4,4{40 -tetrahydro-4,4{40 -dioxo(6,6{40 biquinoline)-2,2{40 -dicarboxylates | |
US3982006A (en) | M-Phenylene dioxamic acid derivatives | |
US3888983A (en) | Derivatives of thiazolino-pyrimidin-6-ones, in inducing analgesia | |
US4119783A (en) | 3'Lower alkylcarbonyl oxanilic acid esters | |
US3530126A (en) | N-heterocyclic substituted cyclohexanes | |
US3714354A (en) | Bronchodilator activity of substituted quinazolinecarboxylic acid esters | |
US3816467A (en) | 4-oxo-4h-pyrano(3,2-b)benzofuran-2-carboxylic acids and salts thereof | |
US3953598A (en) | Compounds, compositions and methods of use | |
US3838133A (en) | 1,4,5,8,9,12-hexahydro-4,8,12-trioxopyrido(2,3-f) (1,7)phenanthroline-2,6,10-tricarboxylate compounds | |
US3821227A (en) | 4,7 dioxo 12h-cyclopenta (2, 1-8:3,4 g')diquinoline 2,9 dicarboxylic acid derivatives | |
US4067995A (en) | Compounds, compositions and methods of use | |
US4169153A (en) | Anti-allergic oxanilates | |
US4069332A (en) | Compounds, compositions and methods of use |